TAK
Takeda Pharmaceutical Co Ltd
$
15.030
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
15.035
Open
14.930
VWAP
15.00
Vol
1.73M
Mkt Cap
46.95B
Low
14.880
Amount
25.89M
EV/EBITDA(TTM)
9.58
Total Shares
3.14B
EV
10.97T
EV/OCF(TTM)
11.62
P/S(TTM)
1.50
Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q2
FY2026Q1
1.93T
+69.07%
--
--
1.16T
-1.11%
--
--
1.15T
-4.6%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Takeda Pharmaceutical Company Limited (TAK) for FY2026, with the revenue forecasts being adjusted by 0.35% over the past three months. During the same period, the stock price has changed by 1.28%.
Revenue Estimates for FY2026
Revise Upward
+0.35%
In Past 3 Month
Stock Price
Go Up
+1.28%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Takeda Pharmaceutical Co Ltd (TAK.N) is 28.84, compared to its 5-year average forward P/E of 28.35. For a more detailed relative valuation and DCF analysis to assess Takeda Pharmaceutical Co Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
28.35
Current PE
28.84
Overvalued PE
40.76
Undervalued PE
15.95
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Fair
5Y Average EV/EBITDA
9.40
Current EV/EBITDA
9.36
Overvalued EV/EBITDA
10.56
Undervalued EV/EBITDA
8.24
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
1.62
Current PS
1.39
Overvalued PS
1.79
Undervalued PS
1.45
Financials
Annual
Quarterly
FY2025Q4
YoY :
+0.24%
1.05T
Total Revenue
FY2025Q4
YoY :
-281.45%
-74.93B
Operating Profit
FY2025Q4
YoY :
+3343.49%
-103.10B
Net Income after Tax
FY2025Q4
YoY :
+3301.56%
-65.31
EPS - Diluted
FY2025Q4
YoY :
-50.90%
94.56B
Free Cash Flow
FY2025Q4
YoY :
-12.62%
44.45
Gross Profit Margin - %
FY2025Q4
YoY :
+310.73%
13.02
FCF Margin - %
FY2025Q4
YoY :
+3396.43%
-9.79
Net Margin - %
FY2025Q4
YoY :
-100.00%
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
TAK News & Events
Events Timeline
2025-05-19 (ET)
2025-05-19
16:15:41
Veeva has 'meaningful' Life Science head start over Salesforce, says Oppenheimer
2025-05-14 (ET)
2025-05-14
17:09:43
Takeda publishes oveporexton data in New England Journal of Medicine
2025-05-05 (ET)
2025-05-05
08:02:58
Novavax announces improved terms for nuvaxovid agreement with Takeda in Japan
Sign Up For More Events
Sign Up For More Events
News
1.0
05-27NewsfilterTakeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
7.5
05-19Yahoo FinanceSalesforce's Life Sciences Cloud Platform Chosen by Takeda
2.0
05-19SeekingAlphaVeeva down after Takeda chooses Salesforce Life Sciences Cloud
Sign Up For More News
People Also Watch
CPNG
Coupang Inc
28.050
USD
+0.57%
KVUE
Kenvue Inc
23.870
USD
+1.23%
XEL
Xcel Energy Inc
70.100
USD
+0.91%
CTSH
Cognizant Technology Solutions Corp
80.990
USD
+0.42%
ODFL
Old Dominion Freight Line Inc
160.170
USD
-1.14%
IT
Gartner Inc
436.420
USD
+0.20%
GEHC
GE Healthcare Technologies Inc
70.540
USD
-1.38%
CCI
Crown Castle Inc
100.350
USD
0.00%
NET
Cloudflare Inc
165.890
USD
+1.05%
VRSK
Verisk Analytics Inc
314.140
USD
-0.06%
FAQ
What is Takeda Pharmaceutical Co Ltd (TAK) stock price today?
The current price of TAK is 15.03 USD — it has increased 1.55 % in the last trading day.
What is Takeda Pharmaceutical Co Ltd (TAK)'s business?
What is the price predicton of TAK Stock?
What is Takeda Pharmaceutical Co Ltd (TAK)'s revenue for the last quarter?
What is Takeda Pharmaceutical Co Ltd (TAK)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Takeda Pharmaceutical Co Ltd (TAK)'s fundamentals?
How many employees does Takeda Pharmaceutical Co Ltd (TAK). have?